E-ISSN 0976-2779 | ISSN 0975-8453
 

Review Article 


Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra.

Abstract
The endometrial cancer is radiosensitive. Adjuvant radiotherapy is previously said that it may improve survival rate of high-risk endometrial cancer and decrease recurrences rate. This study evaluated overall survival, disease-free survival (DFS) in high risk endometrial cancer, and postradiotherapy side effects. Analytic retrospective research using medical record was conducted. During the 2013-2018 period there were 185 patients with endometrial cancer undergoing radiotherapy. Prognostic factors for OS which are statistically significant were age, BMI, LVSI, stage, waiting time interval, and recurrence. The prognostic factor group of age >60 years significantly had OS (p = 0.04) and DFS-3 years (p = 0.03) which was better than that of the age group <60 years. Obese patients had OS 77% better than the non-obese group (p = 0.02). The LVSI positive group significantly had OS 0% with OR of 0.3 (95% CI 0.1-0.8) (p = 0.02) and DFS-3 years 50% (p = 0.004). Patients with waiting time intervals (queue) >9 weeks had OS 35% (p = 0.03) with OR of 3.2 (95% CI 1.1-8.8), and lower DFS-3 years (76% vs 91%; p = 0.03). Combination of radiotherapy modalities caused 61% of side effects, but statistically not significant. OS and DFS-3 years in patients >60 years old and obese were better than <60 years of age and non-obese. Positive LVSI group had poorer OS and DFS-3 years. The more side effects were due to the combination of modality.

Key words: endometrium, high risk, radiotherapy


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Brahmana Askandar Tjokroprawiro
Articles by Lulus Handayani
Articles by M. Dimas Abdi Putra
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra. Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer. SRP. 2020; 11(5): 192-198. doi:10.31838/srp.2020.5.29


Web Style

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra. Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer. http://www.sysrevpharm.org//?mno=108407 [Access: May 31, 2020]. doi:10.31838/srp.2020.5.29


AMA (American Medical Association) Style

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra. Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer. SRP. 2020; 11(5): 192-198. doi:10.31838/srp.2020.5.29



Vancouver/ICMJE Style

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra. Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer. SRP. (2020), [cited May 31, 2020]; 11(5): 192-198. doi:10.31838/srp.2020.5.29



Harvard Style

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra (2020) Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer. SRP, 11 (5), 192-198. doi:10.31838/srp.2020.5.29



Turabian Style

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra. 2020. Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer. Systematic Reviews in Pharmacy, 11 (5), 192-198. doi:10.31838/srp.2020.5.29



Chicago Style

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra. "Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer." Systematic Reviews in Pharmacy 11 (2020), 192-198. doi:10.31838/srp.2020.5.29



MLA (The Modern Language Association) Style

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra. "Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer." Systematic Reviews in Pharmacy 11.5 (2020), 192-198. Print. doi:10.31838/srp.2020.5.29



APA (American Psychological Association) Style

Brahmana Askandar Tjokroprawiro, Lulus Handayani, M. Dimas Abdi Putra (2020) Outcome and Radiotherapy Side Effects of High-Risk Endometrial Cancer. Systematic Reviews in Pharmacy, 11 (5), 192-198. doi:10.31838/srp.2020.5.29